CORAL GABLES, Fla., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the third quarter and nine months ended September 30, 2015.
“The third quarter was a very productive period for the Catalyst team, with the initiation of the rolling submission of our New Drug Application for the use of Firdapse® in the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)”, said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst. “We expect to complete the submission this quarter and at that time will be requesting a priority review.”
Mr. McEnany added, “We continue to advance our preparations for the planned commercial launch of Firdapse to treat LEMS, and we remain focused on additional development efforts with Firdapse as a potential therapy for other neuromuscular diseases that represent unmet medical needs.”
Help employers find you! Check out all the jobs and post your resume.
